Drug Interaction Between Fluoxetine and Fluvoxamine
Do not combine fluoxetine and fluvoxamine together—this combination is explicitly not recommended and poses significant risks due to overlapping serotonergic mechanisms and potential for serotonin syndrome. 1
Why This Combination Should Be Avoided
Serotonin Syndrome Risk
Both fluoxetine and fluvoxamine are selective serotonin reuptake inhibitors (SSRIs) that enhance serotonergic neurotransmission through the same primary mechanism. The FDA drug label for fluvoxamine explicitly states: "The concomitant use of fluvoxamine with other SSRIs, SNRIs or tryptophan is not recommended." 1
When two SSRIs are combined, the risk of serotonin syndrome increases substantially. This potentially life-threatening condition manifests as:
- Mental status changes (agitation, hallucinations, coma)
- Autonomic instability (tachycardia, labile blood pressure, hyperthermia)
- Neuromuscular aberrations (hyperreflexia, incoordination)
- Gastrointestinal symptoms (nausea, vomiting, diarrhea) 1
Pharmacokinetic Interactions
Beyond the pharmacodynamic serotonergic overlap, these drugs interact at the metabolic level:
- Fluoxetine is a potent inhibitor of CYP2D6 2
- Fluvoxamine is a potent inhibitor of CYP1A2, CYP2C19, CYP3A4, and CYP2C9, with weaker effects on CYP2D6 1
While fluvoxamine is metabolized at least partially by CYP2D6 1, combining it with fluoxetine (a strong CYP2D6 inhibitor) could theoretically increase fluvoxamine levels. Research demonstrates that both drugs can significantly alter the metabolism of other medications through different cytochrome P450 pathways 3, 4, suggesting complex metabolic interactions when used together.
Clinical Implications
There is no therapeutic rationale for combining two SSRIs. If a patient is not responding adequately to one SSRI:
- Switch to the other agent (not combine)
- Allow appropriate washout period given fluoxetine's long half-life (4-6 days for fluoxetine, up to 2 weeks for its active metabolite norfluoxetine)
- Consider augmentation with a non-serotonergic agent
- Consider switching to a different class of antidepressant
Critical Caveat
The FDA label's explicit recommendation against combining fluvoxamine with other SSRIs 1 takes precedence over any theoretical or research considerations. This is a clear contraindication based on mechanism of action and safety profile, prioritizing patient morbidity and mortality.